TD Asset Management Inc Sells 25,722 Shares of Kymera Therapeutics, Inc. $KYMR

TD Asset Management Inc decreased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 10.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 209,248 shares of the company’s stock after selling 25,722 shares during the period. TD Asset Management Inc’s holdings in Kymera Therapeutics were worth $11,843,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. PNC Financial Services Group Inc. increased its position in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after purchasing an additional 770 shares during the period. Osaic Holdings Inc. increased its holdings in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the period. Bessemer Group Inc. raised its stake in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after buying an additional 815 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Kymera Therapeutics in the 2nd quarter valued at $73,000. Finally, Lazard Asset Management LLC bought a new position in shares of Kymera Therapeutics during the 2nd quarter worth about $116,000.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera announced its degrader candidate KT‑579 has entered first‑in‑human (Phase 1) testing — an important de‑risking milestone that validates the Pegasus platform and expands the company’s clinical-stage pipeline. Article Title
• Positive Sentiment: Management reported a large cash infusion (~$1.6B) that materially extends the company’s cash runway into 2029 and supports planned development (including KT‑621), reducing near‑term dilution risk. This funding, combined with ongoing program progress, is a key positive for valuation and execution. Article Title
• Positive Sentiment: Analyst sentiment remains constructive: Piper Sandler raised its price target to $140 and the consensus analyst posture is still broadly a “Buy,” supporting potential upside from upgrades and model revisions. Article Title
• Neutral Sentiment: Kymera reiterated plans to read out KT‑621 Phase IIb data in 2027 — a clear catalyst for 2027 but distant; this keeps the company in a development‑stage timeline where interim updates will matter to sentiment. Article Title
• Negative Sentiment: Q4 results missed expectations — EPS of ($0.97) vs. consensus ($0.77) and revenue of $2.87M vs. $14.8M (down ~60% y/y). The larger loss and revenue shortfall triggered near‑term selling and raises questions on near‑term commercial/collaboration cadence. Article Title
• Negative Sentiment: Insider selling: CEO Nello Mainolfi sold 30,000 shares (~$2.7M). While not uncommon for executives to monetize, multiple recent sales may weigh on investor sentiment in the short term. Article Title

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $91.35 on Monday. The company has a market cap of $7.46 billion, a price-to-earnings ratio of -24.82 and a beta of 2.20. The stock’s fifty day moving average price is $78.52 and its two-hundred day moving average price is $65.62. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same quarter in the previous year, the firm earned ($0.88) EPS. The company’s revenue was down 60.8% compared to the same quarter last year. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright upped their target price on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Royal Bank Of Canada restated an “outperform” rating and issued a $108.00 target price on shares of Kymera Therapeutics in a research note on Thursday. Citigroup raised their price objective on shares of Kymera Therapeutics from $80.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Wells Fargo & Company lifted their price objective on Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. Finally, Jefferies Financial Group increased their target price on Kymera Therapeutics from $73.00 to $122.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $117.60.

Insider Activity

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $89.76, for a total transaction of $448,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the transaction, the chief executive officer owned 666,195 shares in the company, valued at approximately $60,130,760.70. The trade was a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 450,895 shares of company stock worth $40,486,151. Corporate insiders own 16.01% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.